Anastrozole and Fulvestrant in Metastatic Breast Cancer REPLY

被引：1

作者：

Mehta, Rita S. ^{[1
]}

Barlow, William E. ^{[2
]}

Hortobagyi, Gabriel N. ^{[3
]}

机构：

[1] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA

[2] SWOG Stat Ctr, Seattle, WA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 17期

关键词：

D O I：

10.1056/NEJMc1210463

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1663 / 1664

页数：2

共 4 条

[1] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer [J].

Bergh, Jonas ;

Jonsson, Per-Ebbe ;

Lidbrink, Elisabet Kerstin ;

Trudeau, Maureen ;

Eiermann, Wolfgang ;

Brattstrom, Daniel ;

Lindemann, Justin P. O. ;

Wiklund, Fredrik ;

Henriksson, Roger .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1919-1925

[2] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer (vol 28, pg 4594, 2010) [J].

Di Leo, A. ;

Jerusalem, G. ;

Petruzelka, L. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2293-2293

[3]

Johnston S, 2012, 8 EUR BREAST CANC C

[4] Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study [J].

Robertson, John F. R. ;

Llombart-Cussac, Antonio ;

Rolski, Janusz ;

Feltl, David ;

Dewar, John ;

Macpherson, Euan ;

Lindemann, Justin ;

Ellis, Matthew J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4530-4535

← 1 →